Providers

The frequency of global crises such as hurricanes, war, and the pandemic makes a standing committee necessary.

Patients who received early immunosuppressive therapy for their rheumatoid arthritis (RA)–associated peripheral ulcerative keratitis experienced earlier inflammatory control, fewer recurrences, and better visual outcomes.

Investigators said these differences might help explain why some patients have better outcomes than others with combination immune checkpoint blockades.

Expression of the chemokine receptor was linked with better overall survival.

Patients may have unrealistic expectations of how a new treatment or procedure may help them, and the conversation between the patient and physician is crucial for setting expectations, explained Robert G. Fante, MD, FACS, president of the American Society of Ophthalmic Plastic & Reconstructive Surgery and facial plastic surgeon and cosmetic surgeon, Fante Eye & Face Centre in Denver, Colorado.

Other gastrointestinal disorders and inflammatory diseases have also been linked to psychiatric disorders, but not much is known about the connection to eosinophilic esophagitis (EoE).

The association between higher disease activity risk of cardiovascular (CV) events was strongest during the first 6 months of follow-up, the study found.

Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, addresses considerations for getting a second COVID-19 booster, or a fourth dose, among survivors of breast cancer or patients currently undergoing treatment as well as those who may be immunocompromised.

Predictive models can help find high-risk patients with asthma and manage them proactively, but prior models miss the highest-risk patients and may mislabel low-risk patients.

Alymsys from Amneal Pharmaceuticals and mAbxience is the third biosimilar referencing Avastin approved in the United States and the second of 3 biosimilar approvals Amneal expects in 2022.

This new literature review explored the potential to enhance management for type 1 diabetes (T1D) through the adoption of physiological parameters measured by wearable and sensor-enabled health-related technology.

Delayed diagnosis of wild-type transthyretin amyloid cardiomyopathy (ATTR-CM) results in inappropriate treatments prior to diagnosis and worse clinical outcomes after diagnosis.

News on 2 new CAR T-cell therapies and updates on PARP inhibitors, BTK inhibitors, and biosimilars.

Coverage from the Community Oncology Alliance 2022 Community Oncology Conference, held March 17-18 in Kissimmee, Florida.

Accenture’s 2021 report, “The Future Is Now: How to Drive Precision Oncology Adoption," adds to the chorus calling for greater sharing of data and improved standardization, so that academic centers and community practices alike can continually improve data sets used worldwide.

Across OneOncology, says Edward Arrowsmith MD, MPH, clinical pathways offer a vehicle for physicians to agree on best practices and to implement them across the network. Early this year, Arrowsmith became medical director for Clinical Pathways, OneOncology.

Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, explains current knowledge on the pathology of atopic dermatitis and use of targeted biologic therapies.

Editor’s Note: After this issue of Evidence-Based Oncology™ went to press, Bristol Myers Squibb Foundation announced the $100 million, 5-year initiative will now be called the Robert A. Winn Diversity in Clinical Trials Award Program. The program will also receive a $14 million donation from Gilead Sciences, Inc., over the next 4 years.

Using data from the National HIV Surveillance System, the National Center for Health Statistics, and the US Census, a team from the CDC investigated lifetime HIV risk in the United States.

It is not yet clear what impact proactive screening might have on health care costs and survival outcomes.

In this contributor piece, the connection between the complexities of mental health and heart disease in at-risk communities is explored, with the authors stressing the importance of risk factor evaluation and multidisciplinary patient education from both mental and physical health providers.

Findings of a survey of large employers indicate that utilization management tools are ineffective in controlling health care costs for employees and may lead to barriers to treatment.

Reduced health-related quality of life was identified in patients with chronic rhinosinusitis with nasal polyps compared with the general population—regardless of previous sinus surgery or presence of comorbidities.

This new study used data on women with stage 0 to II breast cancer to investigate their long-term quality of life (QOL) as it related to choice of surgery and the decision to undergo adjuvant radiation therapy.

In Medicaid, delivering care needs to address the lack of resources and other socioeconomic factors that impact patients, said Steve Evans, MD, chief medical officer of SilverSummit at Centene.

Improvements in time spent in target range and glycated hemoglobin A1c were investigated among 34 children with type 1 diabetes (T1D) with a history of daily insulin use and no prior use of diabetes technology.

In patients with intermediate- to high-risk, use of pegfilgrastim biosimilars could optimize management of FN risk.

Patient-reported treatment goals for psoriasis showed varied preferences according to characteristics such as age, severity, and gender, but the top goal overall was to have confidence in the therapy.

Across 3 disease states, dupilumab has been shown to create rapid, clinically meaningful responses that were sustained, which could improve adherence and the patient-provider relationship.

While teprotumumab, a new FDA-approved therapy for thyroid eye disease (TED), has its adverse events, the other options to treat TED can have severe consequences, said Shoaib Ugradar, MD, UCLA Stein Eye Center Santa Monica.